Subclinical Hypothyroidism as a Risk for Coronary Artery Bypass Grafting

IF 2.8 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Therapeutics Pub Date : 2026-01-12 DOI:10.1155/cdr/9940175

Ricardo Mendes Martins, Felipe José M. Pittella, Beatriz C. de Oliveira, Bernardo G. S. Lima, Caio C. Ferreira, Aline D. Pereira, Wolney A. Martins, Rubens A. C. Filho, Giovanna A. B. Lima

{"title":"Subclinical Hypothyroidism as a Risk for Coronary Artery Bypass Grafting","authors":"Ricardo Mendes Martins, Felipe José M. Pittella, Beatriz C. de Oliveira, Bernardo G. S. Lima, Caio C. Ferreira, Aline D. Pereira, Wolney A. Martins, Rubens A. C. Filho, Giovanna A. B. Lima","doi":"10.1155/cdr/9940175","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>The relationship between hypothyroidism and cardiovascular disease is well established. However, data on subclinical hypothyroidism (SH) and its impact on major adverse cardiovascular events (MACEs) and postoperative complications following coronary artery bypass grafting (CABG) remain limited. This study was aimed at evaluating whether SH is associated with an increased risk of these outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>From 2010 to 2019, 863 patients who underwent CABG for cardiovascular diseases at a reference center were included. The primary outcomes included MACE (composite and individual events: all-cause death, cardiovascular death, stroke, acute myocardial infarction [AMI], and new revascularization) and postoperative complications, including atrial fibrillation (AF), pleural effusion (PLE), pericardial effusion (PCE), infections at any site (IASs), and mediastinitis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>SH patients had higher rates of MACE (20.3% vs. 8.2%, <i>p</i> = 0.001), MACE 4p (22.0% vs. 12.9%, <i>p</i> = 0.002), and stroke (10.2% vs. 3.0%, <i>p</i> = 0.013) than those of euthyroid patients. No significant differences were observed in all-cause death, cardiovascular death, AMI, or new revascularization. Postoperative complications were also more frequent in the SH group: AF (18.6% vs. 9.7%, <i>p</i> = 0.043), PLE (52.6% vs. 19.2%, <i>p</i> < 0.0001), PCE (20.3% vs. 7.8%, <i>p</i> = 0.03), and IAS (28.8% vs. 16.9%, <i>p</i> = 0.032). However, no significant difference was noted in the incidence of mediastinitis.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>SH patients who underwent CABG had a higher frequency of MACE and postoperative complications than those of euthyroid patients.</p>\n </section>\n </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12796499/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/cdr/9940175","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The relationship between hypothyroidism and cardiovascular disease is well established. However, data on subclinical hypothyroidism (SH) and its impact on major adverse cardiovascular events (MACEs) and postoperative complications following coronary artery bypass grafting (CABG) remain limited. This study was aimed at evaluating whether SH is associated with an increased risk of these outcomes.

Methods

From 2010 to 2019, 863 patients who underwent CABG for cardiovascular diseases at a reference center were included. The primary outcomes included MACE (composite and individual events: all-cause death, cardiovascular death, stroke, acute myocardial infarction [AMI], and new revascularization) and postoperative complications, including atrial fibrillation (AF), pleural effusion (PLE), pericardial effusion (PCE), infections at any site (IASs), and mediastinitis.

Results

SH patients had higher rates of MACE (20.3% vs. 8.2%, p = 0.001), MACE 4p (22.0% vs. 12.9%, p = 0.002), and stroke (10.2% vs. 3.0%, p = 0.013) than those of euthyroid patients. No significant differences were observed in all-cause death, cardiovascular death, AMI, or new revascularization. Postoperative complications were also more frequent in the SH group: AF (18.6% vs. 9.7%, p = 0.043), PLE (52.6% vs. 19.2%, p < 0.0001), PCE (20.3% vs. 7.8%, p = 0.03), and IAS (28.8% vs. 16.9%, p = 0.032). However, no significant difference was noted in the incidence of mediastinitis.

Conclusions

SH patients who underwent CABG had a higher frequency of MACE and postoperative complications than those of euthyroid patients.

Abstract Image

查看原文本刊更多论文

亚临床甲状腺功能减退是冠状动脉搭桥术的危险因素。

背景：甲状腺功能减退症与心血管疾病之间的关系已经确立。然而，关于亚临床甲状腺功能减退症（SH）及其对冠状动脉旁路移植术（CABG）后主要不良心血管事件（mace）和术后并发症的影响的数据仍然有限。本研究旨在评估SH是否与这些结果的风险增加有关。方法：2010年至2019年，在参考中心接受心血管疾病冠脉搭桥治疗的863例患者纳入研究。主要结局包括MACE（复合和个体事件：全因死亡、心血管死亡、卒中、急性心肌梗死[AMI]和新的血血重建术）和术后并发症，包括心房颤动（AF）、胸腔积液（PLE）、心包积液（PCE）、任何部位感染（IASs）和纵隔炎。结果：甲状腺功能低下患者的MACE发生率（20.3%比8.2%,p = 0.001）、MACE 4p发生率（22.0%比12.9%,p = 0.002）和卒中发生率（10.2%比3.0%,p = 0.013）均高于甲状腺功能正常患者。在全因死亡、心血管死亡、AMI或新的血运重建术方面没有观察到显著差异。SH组术后并发症发生率也更高：AF（18.6%比9.7%,p = 0.043）、PLE（52.6%比19.2%,p < 0.0001）、PCE（20.3%比7.8%,p = 0.03）、IAS（28.8%比16.9%,p = 0.032）。然而，纵隔炎的发生率无显著差异。结论：行CABG的SH患者MACE发生率及术后并发症均高于甲状腺功能正常的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Therapeutics 医学-心血管系统

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.